'Stay calm' and 'this is the new normal': What banking CEOs are saying about the global market sell-off
CNBC· 2026-01-20 12:29
Stock Chart IconStock chart iconStoxx 600 Europe.With fears of a re-run of last April's "Liberation Day" tariff turmoil looming over the World Economic Forum gathering in Davos, bank CEOs in Europe called for cool heads around the prospect of a renewed trade war."It's important to stay calm," Commerzbank CEO Bettina Orlopp told CNBC's "Squawk Box Europe" on Tuesday. "If anything told us from last year's [tariff] event, it's best to stay calm and see what's really happening."watch nowEuropean banks were amo ...
Elon Musk and Ryanair's CEO call each other ‘idiots.' The numbers say something else.

MarketWatch· 2026-01-20 12:27
Elon Musk and Michael O'Leary are calling each other idiots — but shareholders of both companies would reject that charge. ...
Oil News: China Oil Demand Counters Trump Tariffs, Futures Test Upper Range
FX Empire· 2026-01-20 12:26
EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...
BBVA reinstated with an Overweight at JPMorgan
Yahoo Finance· 2026-01-20 12:25
JPMorgan reinstated coverage of BBVA (BBVA) with an Overweight rating and EUR 23.50 price target The firm believes the company can return EUR 30B of capital to shareholders over the next three years. It cites BBVA’s growth, optionality, and “attractive” shareholder returns for the Overweight rating. Claim 50% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BB ...
General Motors Ended 2025 With a Strong Statement for Investors
Yahoo Finance· 2026-01-20 12:25
Key Points Some automakers were derailed by trade policy changes, tariffs, and a disappearing EV tax credit. General Motors led the U.S. auto industry in sales for 2025. Part of GM's sales growth was driven by more affordable Chevy and Buick models. 10 stocks we like better than General Motors › The automotive industry has been quite a bumpy ride in 2025. The industry dealt with a rapidly evolving transition to electric vehicles (EVs) that was partially derailed by changing trade policy, tariffs, ...
D.R. Horton Earnings Top Estimates but ‘Cautious’ Homebuyers Impacting Demand
Barrons· 2026-01-20 12:23
D.R. Horton earnings beat analysts' expectations but the home builder warned that potential buyers are still being cautious. ...
3M Sees Faster Revenue Growth in 2026 After Strong 4th-Quarter Sales
WSJ· 2026-01-20 12:22
3M is projecting faster revenue growth in 2026 after closing out the fourth quarter with an uptick in sales. ...
Volvo upgraded to Buy from Hold at Nordea
Yahoo Finance· 2026-01-20 12:20
Nordea analyst Agnieszka Vilela upgraded Volvo (VLVLY) to Buy from Hold with a SEK 36 price target The company is well positioned to benefit from a better truck industry outlook in North America, the analyst tells investors in a research note. Claim 50% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on VLVLY: Disclaimer & DisclosureReport an Issue ...
GSK to buy food allergy drug maker RAPT in $2.2bn deal
The Guardian· 2026-01-20 12:20
GSK, the UK's second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which is developing a drug that aims to protect against severe food allergies such as nuts, milk and eggs. It is the first large deal announced by GSK's new chief executive, Luke Miels, who joined the London-based company in 2017 as chief commercial officer and took the reins from Emma Walmsley at the start of the year. RAPT Therapeutics is developing therapies for people with inflammatory an ...
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Globenewswire· 2026-01-20 12:19
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further in ...